A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PMID- 28328847
DA  - 20170322
DCOM- 20170410
LR  - 20170410
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 12
DP  - 2017 Mar
TI  - Effect of topical isopropyl unoprostone on macular atrophy progression in eyes
      with exudative age-related macular degeneration.
PG  - e6422
LID - 10.1097/MD.0000000000006422 [doi]
AB  - BACKGROUND: To evaluate the efficacy and safety of topical isopropyl unoprostone 
      (IU) in treating macular atrophy in age-related macular degeneration (AMD)
      patients. METHODS: Fifty-two AMD patients with macular atrophy were included and 
      randomly assigned (1:1) to the treatment (topical 0.15% IU) or placebo group.
      Subjects used study eye drops 3 times a day for 54 weeks. The macular atrophy was
      documented on fundus autofluorescence photographs and measured using
      RegionFinder. The enlargement rate of macular atrophy and the changes in visual
      acuity were examined statistically between baseline and 54 weeks. RESULTS:
      Forty-eight subjects were included in the analyses because 4 subjects withdrew
      from the study. The differences between the IU and placebo groups in mean and
      median area of macular atrophy were not statistically significant at baseline.
      The baseline median lesion size of macular atrophy was 2.33 mm in the IU group
      and 1.63 mm in the placebo group (P = 0.51). The intergroup difference in the
      enlargement ratio of macular atrophy (21 +/- 15% in the IU group and 111 +/- 96% 
      in the placebo group) was statistically significant (P < 0.001). Additionally,
      visual acuity tended to improve over baseline in the IU group. No serious adverse
      events were observed. CONCLUSIONS: Topical IU therapy is safe and effective for
      treating macular atrophy in AMD patients.
FAU - Shiragami, Chieko
AU  - Shiragami C
AD  - aDepartment of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa
      bDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate
      School of Medicine, Kyoto cDepartment of Ophthalmology, Okayama University
      Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama,
FAU - Miyake, Masahiro
AU  - Miyake M
FAU - Fujiwara, Atsushi
AU  - Fujiwara A
FAU - Morizane, Yuki
AU  - Morizane Y
FAU - Tsujikawa, Akitaka
AU  - Tsujikawa A
FAU - Yamashita, Ayana
AU  - Yamashita A
FAU - Shiraga, Fumio
AU  - Shiraga F
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antihypertensive Agents)
RN  - 5M161S5O5P (isopropyl unoprostone)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - Administration, Topical
MH  - Aged
MH  - Aged, 80 and over
MH  - Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Dinoprost/administration & dosage/adverse effects/*analogs &
      derivatives/therapeutic use
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Macular Degeneration/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Visual Acuity
PMC - PMC5371484
EDAT- 2017/03/23 06:00
MHDA- 2017/04/11 06:00
CRDT- 2017/03/23 06:00
AID - 10.1097/MD.0000000000006422 [doi]
AID - 00005792-201703240-00050 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Mar;96(12):e6422. doi: 10.1097/MD.0000000000006422.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b=""  xmlns="" >